These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 10634204)

  • 21. In vitro combination of amdoxovir and the inosine monophosphate dehydrogenase inhibitors mycophenolic acid and ribavirin demonstrates potent activity against wild-type and drug-resistant variants of human immunodeficiency virus type 1.
    Borroto-Esoda K; Myrick F; Feng J; Jeffrey J; Furman P
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4387-94. PubMed ID: 15504868
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reverse transcriptase fidelity and HIV-1 variation.
    Balzarini J; Pelemans H; De Clercq E; Karlsson A; Kleim JP
    Science; 1997 Jan; 275(5297):229-30; author reply 230-1. PubMed ID: 8999551
    [No Abstract]   [Full Text] [Related]  

  • 23. Abacavir (Ziagen).
    Res Initiat Treat Action; 2000 Mar; 6(1):16-7. PubMed ID: 11708178
    [No Abstract]   [Full Text] [Related]  

  • 24. Resistance and cross-resistance to abacavir.
    Moyle G
    HIV Med; 2001 Jul; 2(3):154-62. PubMed ID: 11737395
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multi-drug resistant HIV-1.
    Omrani AS; Pillay D
    J Infect; 2000 Jul; 41(1):5-11. PubMed ID: 10942635
    [No Abstract]   [Full Text] [Related]  

  • 26. Current insights into reverse transcriptase inhibitor-associated resistance.
    Wainberg MA; White AJ
    Antivir Ther; 2001; 6 Suppl 2():11-9. PubMed ID: 11678474
    [No Abstract]   [Full Text] [Related]  

  • 27. Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot study.
    Llibre JM; Bonjoch A; Iribarren J; Galindo MJ; Negredo E; Domingo P; Pérez-Alvarez N; Martinez-Picado J; Schapiro J; Clotet B;
    HIV Med; 2008 Aug; 9(7):508-13. PubMed ID: 18484978
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early intensification with abacavir in subjects at high risk for incomplete viral suppression.
    Bartlett JA; Tebas P; Bassett R; Huang W; Kuritzkes D; Reisler R; Loyack N; Robison K;
    Antivir Ther; 2003 Aug; 8(4):361-3. PubMed ID: 14518706
    [No Abstract]   [Full Text] [Related]  

  • 29. Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with nevirapine, efavirenz or abacavir.
    Ochoa de Echagüen A; Arnedo M; Xercavins M; Martinez E; Rosón B; Ribera E; Domingo P; González A; Riera M; Llibre JM; Gatell JM; Dalmau D;
    AIDS; 2005 Sep; 19(13):1385-91. PubMed ID: 16103769
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.
    Stürmer M; Staszewski S; Doerr HW
    Antivir Ther; 2007; 12(5):695-703. PubMed ID: 17713153
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of reverse transcriptase mutations associated with HIV-1 drug resistance mainly against non-nucleoside reverse transcriptase inhibitors in treatment-naive patients.
    Magiorkinis E; Paraskevis D; Lazanas M; Kiosses VG; Gargalianos P; Hatzakis A
    AIDS; 1999 Jul; 13(10):1276-8. PubMed ID: 10416535
    [No Abstract]   [Full Text] [Related]  

  • 32. [Current situation of nucleoside reverse transcriptase inhibitors].
    Ngo Van P
    Ann Med Interne (Paris); 2000 Jun; 151(4):255-9. PubMed ID: 10922952
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro anti-HIV-1 synergy between non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz.
    Kollmann C; Tremblay C; Giguel F; Chou TC; Hirsch MS
    Antivir Ther; 2001 Jun; 6(2):143-4. PubMed ID: 11491419
    [No Abstract]   [Full Text] [Related]  

  • 34. Mycophenylate - a potential new option.
    Proj Inf Perspect; 1999 Sep; (28):9. PubMed ID: 11367367
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical utility of resistance testing.
    Stebbing J; Gazzard BG
    J HIV Ther; 2002 Nov; 7(4):75-9. PubMed ID: 12733604
    [No Abstract]   [Full Text] [Related]  

  • 36. Highly active antiretroviral therapy failure and protease and reverse transcriptase human immunodeficiency virus type 1 gene mutations.
    Monno L; Appice A; Cavaliere R; Scarabaggio T; Angarano G
    J Infect Dis; 1999 Aug; 180(2):568-71. PubMed ID: 10395885
    [No Abstract]   [Full Text] [Related]  

  • 37. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain.
    Gómez-Cano M; Rubio A; Puig T; Pérez-Olmeda M; Ruiz L; Soriano V; Pineda JA; Zamora L; Xaus N; Clotet B; Leal M
    AIDS; 1998 Jun; 12(9):1015-20. PubMed ID: 9662197
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Primary lamivudine resistance in acute/early human immunodeficiency virus infection.
    Conway B; Montessori V; Rouleau D; Montaner JS; O'Shaughnessy MV; Fransen S; Shillington A; Weislow O; Mayers DL
    Clin Infect Dis; 1999 Apr; 28(4):910-1. PubMed ID: 10825060
    [No Abstract]   [Full Text] [Related]  

  • 39. Molecular basis of antagonism between K70E and K65R tenofovir-associated mutations in HIV-1 reverse transcriptase.
    Kagan RM; Lee TS; Ross L; Lloyd RM; Lewinski MA; Potts SJ
    Antiviral Res; 2007 Sep; 75(3):210-8. PubMed ID: 17442410
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Resistance against reverse transcriptase inhibitors.
    O'Brien WA
    Clin Infect Dis; 2000 Jun; 30 Suppl 2():S185-92. PubMed ID: 10860904
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.